(1888PressRelease)
June 12, 2008 - MONROVIA, CA – Dr. Alain Delcayre, Director of Research at BN ImmunoTherapeutics will be speaking at GTCbio’s 2nd Protein Therapeutics Discovery & Development conference on September 8-9, 2008 in San Diego, CA. Dr. Gonzalez will present on recombinant protein design for the generation of particle-bound and targeted therapeutics using natural and synthetic vesicles as delivery vehicles.
The pharmacodynamic properties of therapeutics are critical parameters that contribute to drug efficacy.
They have significant bearing on the determination of treatment regimen and doses and consequently also affect benefit/safety ratio as well as cost of treatment. Drug features leading to improved efficacy include particle-bound formulation, which can increase the stability /half life of compounds, and targeted delivery.
In addition to improving efficacy, these features may contribute to achieve clinical benefits using lower drug doses, thereby potentially limiting drug-related side effects. BN ImmunoTherapeutics has developed a technology called Exosome Display that enable the manipulation of the protein content of naturally occurring exosomal vesicles as well as the efficient loading of synthetic vesicles with therapeutic protein and/or ligand for targeted delivery of therapeutic compounds.
GTCbio’s 2nd Annual Protein Therapeutics Discovery and Development Conference will explore the therapeutic applications of proteins, with a look at discovery and design of therapeutics, overcoming challenges associated with protein based drugs, and new tools and strategies in process development.
Finally, attendees will get an update on novel developments in protein therapeutics. The keynote presentation will be given by Dr. Michael Hanley, Vice President of Discovery Research & CSO of Amylin Pharmaceuticals. For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=128.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact:
GTCBIO (626) 256-6405,
(626) 256-6460 fax,
Jason.yi ( @ ) gtcbo dot com
###
